The long-term goal of this proposal is to understand the molecular mechanisms underlying cell-specific and hypoxia-inducible expression of the human EPO gene. The applicant will continue his previous studies which have characterized cis-acting elements and their associated protein factors which mediate this complex regulation. The PI has shown that DNA sequences located 6-14 kb 5' of the EPO gene are required for its expression in the kidneys of transgenic mice. This region will be analyzed more fully in transgenic mice by utilizing progressively smaller segments of it to drive EPO gene expression. He will also determine whether these regions can function independently of an enhancer located in the 3' flanking region. He will also attempt to identify elements >14 kb upstream of the gene which appear to be necessary for post-natal down-regulation of EPO gene expression in the liver. A hypoxia-inducible factor (HIF-1), that binds to the EPO gene 3' enhancer site, has been purified and partial cDNA clones have been identified. Full-length cDNAs and bacterially expressed fusion proteins for the production of antisera will be obtained. These will be used to establish the kinetics of HIF-1 mRNA and protein expression in normoxic, hypoxic, and post-hypoxic cells. This should permit the PI to establish the molecular mechanisms by which HIF-1 DNA binding activity is induced and EPO gene transcription is activated. An additional factor that binds to the 3' enhancer and collaborates with HIF-1 for EPO transcriptional activation will also be characterized.

National Institute of Health (NIH)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Research Project (R01)
Project #
Application #
Study Section
Hematology Subcommittee 2 (HEM)
Program Officer
Badman, David G
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Johns Hopkins University
Schools of Medicine
United States
Zip Code
Semenza, Gregg L (2003) Angiogenesis in ischemic and neoplastic disorders. Annu Rev Med 54:17-28
Cai, Zheqing; Manalo, Dominador J; Wei, Guo et al. (2003) Hearts from rodents exposed to intermittent hypoxia or erythropoietin are protected against ischemia-reperfusion injury. Circulation 108:79-85
Kelly, Brian D; Hackett, Sean F; Hirota, Kiichi et al. (2003) Cell type-specific regulation of angiogenic growth factor gene expression and induction of angiogenesis in nonischemic tissue by a constitutively active form of hypoxia-inducible factor 1. Circ Res 93:1074-81
Fukuda, Ryo; Hirota, Kiichi; Fan, Fan et al. (2002) Insulin-like growth factor 1 induces hypoxia-inducible factor 1-mediated vascular endothelial growth factor expression, which is dependent on MAP kinase and phosphatidylinositol 3-kinase signaling in colon cancer cells. J Biol Chem 277:38205-11
Semenza, Gregg L (2002) Physiology meets biophysics: visualizing the interaction of hypoxia-inducible factor 1 alpha with p300 and CBP. Proc Natl Acad Sci U S A 99:11570-2
Shimoda, L A; Manalo, D J; Sham, J S et al. (2001) Partial HIF-1alpha deficiency impairs pulmonary arterial myocyte electrophysiological responses to hypoxia. Am J Physiol Lung Cell Mol Physiol 281:L202-8
Hirota, K; Semenza, G L (2001) Rac1 activity is required for the activation of hypoxia-inducible factor 1. J Biol Chem 276:21166-72
Mahon, P C; Hirota, K; Semenza, G L (2001) FIH-1: a novel protein that interacts with HIF-1alpha and VHL to mediate repression of HIF-1 transcriptional activity. Genes Dev 15:2675-86
Semenza, G L (2001) Hypoxia-inducible factor 1: control of oxygen homeostasis in health and disease. Pediatr Res 49:614-7
Laughner, E; Taghavi, P; Chiles, K et al. (2001) HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol Cell Biol 21:3995-4004

Showing the most recent 10 out of 48 publications